Currently it only shows your basic business info. Start adding relevant business details such as description, images and products or services to gain your customers attention by using Boost 360
android app
/
iOS App/ web portal.
{
"products": [
{
"_id": "665ef17474d94b15a06c31e2",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "gliclazide 40mg metformin 500 mg",
"description": "GLICLAGLAZE M 40 \ngliclazide 40mg metformin 500 mg\nIntroduction\nGLICLAGLAZE M 40 is a combination medication designed to manage blood sugar levels in individuals with Type 2 diabetes. This oral treatment integrates two potent antidiabetic agents: Gliclazide (40 mg) and Metformin (500 mg), each playing a crucial role in diabetes control.\n\nHow It Works\n\nGliclazide (40 mg): As a sulfonylurea, Gliclazide works by stimulating the release of insulin from the pancreatic beta cells. Insulin is the hormone responsible for reducing blood glucose levels. Gliclazide also enhances the sensitivity of peripheral tissues to insulin and reduces the likelihood of clot formation, which is a common complication in diabetes patients.\nMetformin (500 mg): Metformin acts primarily by reducing glucose production in the liver. It also improves insulin sensitivity, enhancing peripheral glucose uptake and utilization. Unlike many other antidiabetic medications, Metformin does not cause hypoglycemia (low blood sugar) and is often associated with weight loss.\nBenefits\nThe dual mechanism of GLICLAGLAZE M 40 offers a comprehensive approach to diabetes management by not only improving insulin production and sensitivity but also addressing the hepatic release of glucose. This combination reduces blood sugar levels effectively while minimizing the risk of side effects common to other diabetes treatments, such as hypoglycemia.\n\nUsage Guidelines\n\nDosage: Typically, the initial dosage is guided by the patient’s current treatment regimen, effectiveness, and tolerability. Adjustment in dosage should be made based on the patient’s blood glucose response, under the supervision of a healthcare provider.\nAdministration: GLICLAGLAZE M 40 should be taken with meals to reduce gastrointestinal side effects and to enhance absorption.\nSide Effects\nWhile GLICLAGLAZE M 40 is generally well-tolerated, it may cause some side effects. Common ones include gastrointestinal disturbances such as nausea and diarrhea, which are often transient. Hypoglycemia may occur, but it is less frequent due to the mitigating action of Metformin.\n\nConclusion\nGLICLAGLAZE M 40 is a cornerstone in the pharmacological treatment of Type 2 diabetes, offering benefits derived from the combined effects of Gliclazide and Metformin. It is essential for patients to follow their healthcare provider’s instructions and to maintain regular check-ups to optimize treatment outcomes and prevent complications. This medication enables patients to manage their diabetes more effectively and improve their quality of life.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n Order Now\n\n\n\n\n\n\n\n",
"price": 149.0,
"discountamount": 44.7,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 7,
"_keywords": [
"life",
"risk",
"liver",
"meals",
"40 mg",
"Order",
"EMAIL",
"500 mg",
"nausea",
"quality",
"hormone",
"diarrhea",
"Benefits",
"Metformin",
"gliclazide",
"Adjustment",
"likelihood",
"Conclusion",
"absorption",
"utilization",
"cornerstone",
"information",
"supervision",
"individuals",
"weight loss",
"sulfonylurea",
"hypoglycemia",
"Introduction",
"tolerability",
"sterisonline",
"instructions",
"sterispharma",
"crucial role",
"complications",
"GLICLAGLAZE M",
"CALL/WHATSAPP",
"effectiveness",
"oral treatment",
"dual mechanism",
"clot formation",
"Administration",
"initial dosage",
"Type 2 diabetes",
"hepatic release",
"low blood sugar",
"diabetes control",
"combined effects",
"mitigating action",
"diabetes patients",
"regular check-ups",
"blood sugar levels",
"treatment outcomes",
"peripheral tissues",
"glucose production",
"insulin production",
"diabetes management",
"insulin sensitivity",
"common complication",
"healthcare provider",
"blood glucose levels",
"pancreatic beta cells",
"combination medication",
"blood glucose response",
"comprehensive approach",
"Usage Guidelines Dosage",
"pharmacological treatment",
"peripheral glucose uptake",
"current treatment regimen",
"other diabetes treatments",
"gastrointestinal disturbances",
"gastrointestinal side effects",
"two potent antidiabetic agents",
"many other antidiabetic medications"
],
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 1284,
"imageuri": "https://productimages.withfloats.com/actual/665ef175c06ee12d88caa810.png",
"tileimageuri": "https://productimages.withfloats.com/tile/665ef175c06ee12d88caa810.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2024-06-04T10:50:28.577Z",
"updatedon": "2026-03-13T05:35:17.063Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM/products/gliclazide-40mg-metformin-500-mg/1284",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "GLICLAGLAZE M 40 ",
"category": "DIABETIC RANGE",
"tags": [
"gliclazide 40mg metformin 500 mg tablet uses",
"gliclazide 40mg metformin 500 mg dosage for diabetes",
"gliclazide metformin 40 mg 500 mg side effects",
"gliclazide 40mg metformin 500 mg tablet for type 2 diabetes",
"gliclazide metformin combination tablet information",
"gliclazide metformin 40mg 500mg blood sugar control",
"buy gliclazide 40mg metformin 500 mg tablets online",
"order gliclazide metformin tablets online india",
"gliclazide metformin bulk purchase online",
"gliclazide 40mg metformin 500 mg uses dosage and side effects",
"buy gliclazide 40mg metformin 500 mg tablets online best price",
"gliclazide 40mg metformin 500 mg price in india"
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": "",
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.001,
"isnotforsale": false
},
{
"_id": "69afcdd7726d81b4833817a9",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "metformin linagliptin",
"description": "Advanced Combination Therapy with Metformin and Linagliptin for Effective Blood Sugar Control\n\nManaging type 2 diabetes requires consistent care, the right medication, and lifestyle management to maintain healthy blood glucose levels. Modern diabetes treatment often uses combination therapies that work through different mechanisms to provide better control and long-term health benefits. LINALIGOLD M 2.5/1000 is a scientifically formulated anti-diabetic medication that combines Metformin (1000 mg) and Linagliptin (2.5 mg) to help manage blood sugar levels effectively in adults with type 2 diabetes mellitus.\n\nThis dual-action tablet is designed to improve glycemic control when diet and exercise alone are not sufficient. By targeting different pathways involved in glucose regulation, LINALIGOLD M 2.5/1000 helps maintain stable blood sugar levels, supports metabolic health, and reduces the risk of diabetes-related complications.\n\nProduct Description\n\nLINALIGOLD M 2.5/1000 is a combination anti-diabetic medication that brings together two well-established drugs used in diabetes management: Metformin, a biguanide that reduces glucose production in the liver and improves insulin sensitivity, and Linagliptin, a DPP-4 inhibitor that enhances the body’s natural ability to regulate blood sugar levels.\n\nThis powerful combination works synergistically to control blood glucose levels throughout the day. While Metformin helps decrease the amount of sugar released into the bloodstream from the liver, Linagliptin increases the activity of incretin hormones, which stimulate insulin release when blood sugar levels are high.\n\nLINALIGOLD M 2.5/1000 is commonly prescribed for patients with type 2 diabetes mellitus who require improved glycemic control and who may not achieve adequate results with a single medication.\n\nKey Ingredients and Their Role\nMetformin (1000 mg)\n\nMetformin is one of the most widely used medications for the treatment of type 2 diabetes. It works primarily by:\n\nReducing glucose production in the liver\n\nImproving the body's sensitivity to insulin\n\nIncreasing glucose uptake by muscle cells\n\nReducing absorption of glucose from the intestines\n\nThese actions help lower fasting and post-meal blood sugar levels while supporting overall metabolic balance.\n\nLinagliptin (2.5 mg)\n\nLinagliptin belongs to a class of medications known as DPP-4 inhibitors. It works by increasing levels of incretin hormones in the body, which help regulate blood glucose levels. Its actions include:\n\nStimulating insulin release after meals\n\nReducing excessive glucose production by the liver\n\nLowering postprandial (after meal) blood sugar levels\n\nSupporting natural glucose regulation without causing sudden drops in blood sugar\n\nTogether, these two ingredients provide a comprehensive approach to diabetes management.\n\nUses of LINALIGOLD M 2.5/1000\n\nLINALIGOLD M 2.5/1000 is primarily used for the treatment and management of type 2 diabetes mellitus in adults. It helps maintain proper blood sugar levels and supports long-term metabolic health.\n\n1. Management of Type 2 Diabetes\n\nThis medication is prescribed to help control blood sugar levels in individuals diagnosed with type 2 diabetes when lifestyle modifications alone are not enough.\n\n2. Improvement of Glycemic Control\n\nThe dual mechanism of action helps regulate both fasting and post-meal blood glucose levels, improving overall glycemic control.\n\n3. Prevention of Diabetes Complications\n\nProper management of blood sugar levels helps reduce the risk of diabetes-related complications such as nerve damage, kidney problems, eye disorders, and cardiovascular disease.\n\n4. Support for Insulin Sensitivity\n\nMetformin helps improve the body's response to insulin, making it easier for cells to utilize glucose efficiently.\n\nKey Benefits of LINALIGOLD M 2.5/1000\n1. Dual Mechanism for Better Blood Sugar Control\n\nThe combination of Metformin and Linagliptin provides a two-way approach to controlling blood glucose levels by addressing multiple pathways involved in glucose metabolism.\n\n2. Helps Maintain Stable Blood Sugar Levels\n\nLINALIGOLD M 2.5/1000 helps regulate blood sugar throughout the day, including after meals when glucose levels tend to spike.\n\n3. Supports Natural Insulin Activity\n\nLinagliptin enhances the body's natural insulin response without forcing the pancreas to overwork.\n\n4. Reduces Risk of Blood Sugar Spikes\n\nBy controlling glucose production in the liver and improving insulin efficiency, the medication helps prevent sudden increases in blood sugar.\n\n5. Improves Overall Metabolic Health\n\nRegular use, along with proper diet and exercise, supports better metabolic balance and energy utilization in the body.\n\n6. Convenient Combination Therapy\n\nInstead of taking multiple medications separately, this fixed-dose combination simplifies diabetes management and improves treatment adherence.\n\n7. Lower Risk of Hypoglycemia\n\nCompared with some other diabetes medications, Linagliptin generally carries a lower risk of causing dangerously low blood sugar levels when used appropriately.\n\nHow to Use LINALIGOLD M 2.5/1000\n\nLINALIGOLD M 2.5/1000 should be taken exactly as prescribed by a healthcare professional.\n\nGeneral usage guidelines include:\n\nTake the tablet with food to reduce stomach discomfort.\n\nSwallow the tablet whole with water; do not crush or chew unless advised.\n\nFollow the dosage and schedule recommended by your doctor.\n\nMaintain a healthy diet and regular physical activity for optimal results.\n\nConsistent use is important for maintaining stable blood sugar levels.\n\nPossible Side Effects\n\nLike all medications, LINALIGOLD M 2.5/1000 may cause side effects in some individuals, although not everyone experiences them. Most side effects are mild and temporary as the body adjusts to the medication.\n\nCommon side effects may include:\n\nNausea\n\nDiarrhea\n\nStomach discomfort\n\nLoss of appetite\n\nMild headache\n\nFatigue\n\nLess common but possible side effects include:\n\nUpper respiratory symptoms such as cough or sore throat\n\nMild skin reactions\n\nVitamin B12 deficiency with long-term use of metformin\n\nRare but serious side effects may include:\n\nSevere allergic reactions\n\nLactic acidosis (a rare but serious condition associated with metformin)\n\nPancreatitis in rare cases related to DPP-4 inhibitors\n\nIf symptoms such as severe abdominal pain, unusual weakness, breathing difficulty, or persistent vomiting occur, medical attention should be sought immediately.\n\nPrecautions\n\nBefore taking LINALIGOLD M 2.5/1000, it is important to consult a healthcare professional, especially if you have:\n\nKidney disease\n\nLiver problems\n\nHeart conditions\n\nHistory of pancreatitis\n\nSevere infections or dehydration\n\nAdditional precautions include:\n\nAvoid excessive alcohol consumption.\n\nInform your doctor about all medications you are currently taking.\n\nRegular blood sugar monitoring is recommended.\n\nLifestyle Recommendations for Better Results\n\nMedication works best when combined with healthy lifestyle practices. Patients using LINALIGOLD M 2.5/1000 are encouraged to:\n\nFollow a balanced diabetic-friendly diet\n\nEngage in regular physical activity\n\nMaintain a healthy body weight\n\nMonitor blood glucose levels regularly\n\nAttend routine medical checkups\n\nThese habits can significantly improve diabetes management and overall health.\n\nConclusion\nType 2 diabetes is a chronic condition that requires consistent and effective management to prevent long-term health complications. LINALIGOLD M 2.5/1000 offers a modern combination therapy that integrates the glucose-lowering effects of metformin with the incretin-enhancing action of Linagliptin, providing a comprehensive approach to blood sugar control.",
"price": 154.0,
"discountamount": 46.0,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 1,
"_keywords": null,
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 2323,
"imageuri": "https://productimages.withfloats.com/actual/69afcdd9ea5ba715c39c99dc.png",
"tileimageuri": "https://productimages.withfloats.com/tile/69afcdd9ea5ba715c39c99dc.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2026-03-10T07:52:55.329Z",
"updatedon": "2026-03-13T09:13:04.519Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM//metformin-linagliptin/2323",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "LINALIGOLD M 2.5/1000",
"category": "DIABETIC RANGE",
"tags": [
"metformin and linagliptin tablets for diabetes",
"metformin linagliptin oral diabetes medication",
"linagliptin 2.5 mg metformin 1000 mg tablet",
"medicine for type 2 diabetes metformin linagliptin",
"best medicine combination for type 2 diabetes",
"blood sugar control medicine with metformin",
"tablet for fasting and post meal sugar control",
"how metformin linagliptin works for diabetes",
"metformin linagliptin dosage for type 2 diabetes",
"metformin linagliptin tablet price",
"linagliptin metformin tablets wholesale price",
"LINALIGOLD M metformin linagliptin tablet price",
"LINALIGOLD M tablet for type 2 diabetes",
"metformin linagliptin tablets india",
"linagliptin metformin tablet manufacturer india"
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": null,
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.0,
"isnotforsale": false
},
{
"_id": "69a9837a9c219e2cff873568",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "dapagliflozin glimepiride metformin tablet",
"description": "Composition: Dapagliflozin 10 mg + Glimepiride 2 mg + Metformin Hydrochloride 500 mg (Extended Release)\n\nManaging type 2 diabetes requires a balanced approach that includes proper medication, healthy lifestyle choices, and regular monitoring of blood sugar levels. Modern diabetes management often involves combination therapies that target blood glucose control through multiple mechanisms. One such effective combination medicine is GLIDAPAFLOZIN TRIO 2.\n\nThis medication contains three well-known antidiabetic agents—Dapagliflozin, Glimepiride, and Metformin Hydrochloride in an extended-release formulation. Together, these medicines work in different ways to help control blood sugar levels effectively in adults with type 2 diabetes.\n\nThis article provides a comprehensive overview of the product, its uses, benefits, possible side effects, and important information patients should know before using it.\n\nProduct Overview\n\nGLIDAPAFLOZIN TRIO 2 is a triple-combination oral antidiabetic tablet designed to help manage blood glucose levels in patients diagnosed with Type 2 Diabetes.\n\nEach tablet contains:\n\nDapagliflozin 10 mg\n\nGlimepiride 2 mg\n\nMetformin Hydrochloride 500 mg (Extended Release)\n\nThese ingredients work together to reduce high blood sugar levels through complementary mechanisms, helping patients achieve better glycemic control.\n\nCombination therapy like this is commonly recommended when a single medication alone is not sufficient to manage blood glucose levels.\n\nHow the Medicine Works\n\nThe three active ingredients in GLIDAPAFLOZIN TRIO 2 work through different pathways in the body.\n\n1. Dapagliflozin\n\nDapagliflozin belongs to a class of drugs known as SGLT2 inhibitors. It works by helping the kidneys remove excess glucose from the body through urine. This reduces blood sugar levels and may also provide additional cardiovascular and kidney benefits in some patients.\n\n2. Glimepiride\n\nGlimepiride stimulates the pancreas to release more insulin. Insulin is the hormone responsible for moving glucose from the bloodstream into cells where it can be used as energy.\n\n3. Metformin Hydrochloride (Extended Release)\n\nMetformin Hydrochloride helps lower blood sugar by reducing glucose production in the liver and improving insulin sensitivity in the body. The extended-release formulation ensures a steady release of the medicine over time, improving tolerance and effectiveness.\n\nTogether, these three medicines provide a comprehensive approach to blood sugar management.\n\nUses of GLIDAPAFLOZIN TRIO 2\n\nGLIDAPAFLOZIN TRIO 2 is primarily prescribed for the management of Type 2 Diabetes in adults.\n\nMain Uses\n\nBlood Sugar Control\nThe medication helps reduce high blood glucose levels in patients whose diabetes is not adequately controlled with diet, exercise, or single-drug therapy.\n\nImproving Insulin Function\nIt improves the body’s response to insulin and helps regulate glucose metabolism.\n\nPreventing Diabetes Complications\nProper blood sugar control reduces the risk of long-term complications such as nerve damage, kidney disease, vision problems, and cardiovascular issues.\n\nSupporting Weight and Metabolic Health\nThe presence of dapagliflozin may help some patients experience mild weight reduction and improved metabolic balance.\n\nKey Benefits\n\nThe combination of three effective antidiabetic agents offers several important benefits.\n\n1. Triple Mechanism Action\n\nThe medicine works through three complementary mechanisms, targeting multiple causes of high blood sugar.\n\n2. Better Glycemic Control\n\nPatients often achieve improved HbA1c levels compared to single-drug therapy.\n\n3. Reduced Risk of Long-Term Complications\n\nMaintaining controlled blood sugar levels helps prevent complications associated with diabetes.\n\n4. Convenient Single Tablet Therapy\n\nInstead of taking multiple medicines separately, patients can manage their treatment with a single tablet, improving medication adherence.\n\n5. Extended Release Technology\n\nThe extended-release formulation of Metformin Hydrochloride ensures gradual drug release, reducing stomach discomfort and improving patient tolerance.\n\n6. Improved Energy and Daily Functioning\n\nProper blood sugar control helps patients feel more energetic and maintain better overall health.\n\nPossible Side Effects\n\nLike all medications, GLIDAPAFLOZIN TRIO 2 may cause some side effects. However, not everyone experiences them.\n\nCommon Side Effects\n\nMild stomach discomfort\n\nNausea or vomiting\n\nDiarrhea\n\nHeadache\n\nIncreased urination\n\nLow blood sugar (hypoglycemia), especially when meals are skipped\n\nLess Common Side Effects\n\nUrinary tract infections\n\nDizziness or weakness\n\nMild dehydration\n\nRare but Serious Effects\n\nSevere hypoglycemia\n\nLactic acidosis (very rare but serious condition linked with metformin)\n\nAllergic reactions\n\nPatients should immediately consult a healthcare professional if they experience unusual symptoms such as severe weakness, difficulty breathing, or persistent stomach pain.\n\nPrecautions and Safety Advice\n\nBefore starting GLIDAPAFLOZIN TRIO 2, patients should inform their doctor if they have:\n\nKidney disease\n\nLiver problems\n\nHeart conditions\n\nHistory of severe dehydration\n\nAny known drug allergies\n\nPatients should also avoid skipping meals and maintain proper hydration to reduce the risk of low blood sugar.\n\nRegular monitoring of blood glucose levels is important while using this medication.\n\nLifestyle Tips for Better Results\n\nMedication alone cannot control diabetes. Patients should combine treatment with healthy habits.\n\nRecommended lifestyle practices include:\n\nMaintaining a balanced diabetic diet\n\nExercising regularly\n\nMonitoring blood sugar levels\n\nAvoiding excessive sugar and processed foods\n\nManaging stress levels\n\nGetting sufficient sleep\n\nThese lifestyle changes enhance the effectiveness of diabetes medications.\n\nConclusion\nManaging diabetes requires a consistent and comprehensive approach. Combination medicines like GLIDAPAFLOZIN TRIO 2 provide an effective solution for patients who need stronger glucose control than single-drug therapy can offer.",
"price": 184.0,
"discountamount": 56.0,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 1,
"_keywords": null,
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 2317,
"imageuri": "https://productimages.withfloats.com/actual/69a9837cad119d5b47141190.png",
"tileimageuri": "https://productimages.withfloats.com/tile/69a9837cad119d5b47141190.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2026-03-05T13:22:02.718Z",
"updatedon": "2026-03-13T11:05:08.762Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM//dapagliflozin-glimepiride-metformin-tablet/2317",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "GLIDAPAFLOZIN TRIO 2",
"category": "DIABETIC RANGE",
"tags": [
"dapagliflozin glimepiride metformin tablet uses and dosage",
"dapagliflozin glimepiride metformin combination tablet benefits",
"dapagliflozin glimepiride metformin tablet side effects in adults",
"dapagliflozin glimepiride metformin tablet how it works",
"dapagliflozin glimepiride metformin tablet benefits for sugar control",
"buy dapagliflozin glimepiride metformin tablet online",
"dapagliflozin glimepiride metformin tablet price in india",
"dapagliflozin glimepiride metformin tablet for uncontrolled diabetes",
"dapagliflozin glimepiride metformin tablet triple therapy medicine",
"dapagliflozin glimepiride metformin tablet dosage guide for adults"
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": null,
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.0,
"isnotforsale": false
},
{
"_id": "696e129c1d5e7fc4677fb603",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "metformin hydrochloride 850 mg and Glimepiride 2 mg",
"description": "Diabetes mellitus is one of the most common chronic lifestyle disorders worldwide, affecting millions of people and requiring long-term management. Type 2 diabetes, in particular, occurs when the body either does not produce enough insulin or cannot use insulin effectively. To manage this condition successfully, combination therapy is often recommended when a single medicine is not sufficient to control blood sugar levels.\n\nMetformin Hydrochloride 850 mg and Glimepiride 2 mg Tablets, marketed under the brand name SEIZMET G2 850, is a well-established and effective oral anti-diabetic combination. It is designed to control blood glucose levels through dual action, addressing both insulin resistance and inadequate insulin secretion.\n\nWhat is SEIZMET G2 850?\n\nSEIZMET G2 850 is a combination of two powerful anti-diabetic agents:\n\nMetformin Hydrochloride 850 mg\n\nGlimepiride 2 mg\n\nThis combination is widely prescribed for adults with Type 2 diabetes mellitus when diet, exercise, and monotherapy do not provide adequate glycemic control. By combining two complementary mechanisms, SEIZMET G2 850 helps achieve better and more stable blood sugar management.\n\nUses of Metformin Hydrochloride 850 mg and Glimepiride 2 mg Tablets\n\nThe primary use of SEIZMET G2 850 is the management of Type 2 diabetes mellitus. It is prescribed to:\n\nLower elevated blood glucose levels\n\nImprove insulin sensitivity\n\nEnhance insulin secretion from the pancreas\n\nPrevent diabetes-related complications\n\nThis medicine is especially beneficial for patients who experience persistent high blood sugar despite lifestyle modifications or single-drug therapy.\n\nHow SEIZMET G2 850 Works\n\nSEIZMET G2 850 works through a dual-action mechanism, ensuring effective blood sugar control throughout the day.\n\nRole of Metformin Hydrochloride\n\nMetformin primarily works by:\n\nReducing glucose production in the liver\n\nImproving insulin sensitivity in muscle and fat tissues\n\nDecreasing glucose absorption from the intestine\n\nIt does not cause excessive insulin release, which makes it less likely to cause hypoglycemia when used alone.\n\nRole of Glimepiride\n\nGlimepiride belongs to the sulfonylurea class and works by:\n\nStimulating the pancreas to release insulin\n\nImproving the body’s response to insulin\n\nLowering post-meal blood sugar spikes\n\nTogether, these actions make SEIZMET G2 850 a comprehensive and balanced treatment option for diabetes control.\n\nKey Benefits of SEIZMET G2 850\n\nSEIZMET G2 850 offers several important benefits for patients with Type 2 diabetes:\n\n1. Effective Blood Sugar Control\n\nThe combination ensures both fasting and post-prandial glucose levels remain within the target range.\n\n2. Dual Mechanism for Better Results\n\nBy addressing insulin resistance and insulin deficiency simultaneously, it provides superior glycemic control compared to single-drug therapy.\n\n3. Reduces Risk of Diabetes Complications\n\nProper blood sugar control helps reduce the risk of complications such as nerve damage, kidney disease, eye problems, and cardiovascular disorders.\n\n4. Improves Quality of Life\n\nStable glucose levels lead to better energy levels, improved well-being, and fewer diabetes-related symptoms.\n\n5. Convenient Combination Therapy\n\nCombining two medicines in one tablet improves patient compliance and simplifies daily medication routines.\n\nDosage and Administration\n\nThe dosage of SEIZMET G2 850 should be determined by a healthcare professional based on:\n\nBlood glucose levels\n\nAge and body weight\n\nKidney and liver function\n\nIndividual response to treatment\n\nThe tablet is usually taken once or twice daily with meals to reduce the risk of stomach upset and hypoglycemia. Patients should take the medicine at the same time each day for best results.\n\nIt is important to follow dietary advice, regular exercise, and blood glucose monitoring alongside medication.\n\nPossible Side Effects of SEIZMET G2 850\n\nLike all medicines, Metformin Hydrochloride 850 mg and Glimepiride 2 mg Tablets may cause side effects in some individuals.\n\nCommon Side Effects\n\nNausea\n\nDiarrhea\n\nAbdominal discomfort\n\nHeadache\n\nDizziness\n\nThese side effects are usually mild and temporary and often improve as the body adjusts to the medication.\n\nLess Common but Serious Side Effects\n\nHypoglycemia (low blood sugar), especially if meals are skipped\n\nLactic acidosis (rare but serious, associated with metformin)\n\nAllergic reactions such as skin rash or itching\n\nLiver function abnormalities\n\nPatients should seek medical attention if they experience symptoms such as excessive sweating, confusion, extreme weakness, breathing difficulty, or persistent stomach pain.\n\nPrecautions and Warnings\n\nSEIZMET G2 850 should be used only under medical supervision.\n\nPatients with kidney, liver, or heart disease should inform their doctor before use.\n\nAlcohol consumption should be avoided, as it may increase the risk of side effects.\n\nPregnant and breastfeeding women should consult their doctor before taking this medicine.\n\nRegular monitoring of blood sugar levels is essential to avoid hypoglycemia or uncontrolled diabetes.\n\nWho Should Use SEIZMET G2 850?\n\nSEIZMET G2 850 is suitable for:\n\nAdults diagnosed with Type 2 diabetes\n\nPatients inadequately controlled on metformin or glimepiride alone\n\nIndividuals requiring combination therapy for better glycemic control\n\nIt is not recommended for Type 1 diabetes or diabetic ketoacidosis.\n\nConclusion\n\nMetformin Hydrochloride 850 mg and Glimepiride 2 mg Tablets (SEIZMET G2 850) is a trusted and effective combination therapy for the management of Type 2 diabetes mellitus. By combining the benefits of metformin and glimepiride, it offers comprehensive blood sugar control, reduces the risk of long-term complications, and improves overall quality of life.",
"price": 102.0,
"discountamount": 30.0,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 1,
"_keywords": null,
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 2280,
"imageuri": "https://productimages.withfloats.com/actual/696e12d9cb45a8390116f1bf.png",
"tileimageuri": "https://productimages.withfloats.com/tile/696e12d9cb45a8390116f1bf.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2026-01-19T11:16:44.772Z",
"updatedon": "2026-03-13T11:01:31.908Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM//metformin-hydrochloride-850-mg-and-glimepiride-2-mg/2280",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "SEIZMET G2 850",
"category": "DIABETIC RANGE",
"tags": [
"metformin hydrochloride 850 mg and glimepiride 2 mg tablets",
"metformin 850 mg glimepiride 2 mg combination tablet",
"glimepiride 2 mg with metformin 850 mg tablets",
"metformin glimepiride fixed dose combination tablets",
"metformin 850 mg glimepiride 2 mg dosage",
"metformin glimepiride tablets for type 2 diabetes",
"metformin and glimepiride tablets uses in diabetes",
"metformin 850 mg glimepiride 2 mg for blood sugar control",
"metformin glimepiride tablets mechanism of action",
"metformin glimepiride tablets benefits",
"metformin 850 mg glimepiride 2 mg side effects",
"metformin glimepiride tablets precautions",
"glimepiride metformin tablets safety in diabetes",
"metformin glimepiride tablets contraindications",
"metformin glimepiride tablets warnings",
"metformin glimepiride tablets dosage guidelines",
"how to take metformin 850 mg and glimepiride 2 mg tablets",
"metformin glimepiride tablets before or after food",
"metformin glimepiride tablets daily dose",
"metformin glimepiride tablets price in India"
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": null,
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.0,
"isnotforsale": false
},
{
"_id": "694e56c05837f90c86a7eb8c",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "empagliflozin linagliptin and metformin",
"description": "LINALIGIP EMPAMET (Empagliflozin, Linagliptin, and Metformin Hydrochloride ER Tablets) stands out as a comprehensive triple therapy for adults with type 2 diabetes mellitus, combining three synergistic agents to tackle hyperglycemia from multiple angles. This once-daily extended-release formulation simplifies adherence while delivering robust glycemic control, weight management, and cardiovascular protection. Patients often seek it for its convenience in managing blood sugar levels when diet, exercise, and single agents fall short.\n\n\nProduct Description and Composition\nLINALIGIP EMPAMET features Empagliflozin (typically 10-25mg), Linagliptin (5 mg), and Metformin Hydrochloride ER (up to 1000mg) in a single tablet, designed for prolonged release to minimize gastrointestinal upset. Empagliflozin, an SGLT2 inhibitor, blocks glucose reabsorption in the kidneys, promoting its excretion via urine. Linagliptin, a DPP-4 inhibitor, enhances incretin hormones like GLP-1 to boost insulin secretion and suppress glucagon. Metformin ER reduces hepatic glucose production and improves insulin sensitivity without hypoglycemia risk.\n\n\nThis unique blend from Steris Healthcare ensures steady drug delivery over 24 hours, reducing peak-trough fluctuations for stable HbA1c reductions of 1.5-2.0%. The extended-release metformin coats the tablet core, dissolving gradually in the intestines for better tolerability compared to immediate-release forms. Ideal for Indian patients facing rising diabetes prevalence, it addresses insulin resistance, postprandial spikes, and caloric overload holistically.\n\n\nMechanism of Action\nThe triple mechanism targets key diabetes pathways: Empagliflozin inhibits SGLT2 in proximal renal tubules, lowering blood glucose by 70-90g daily through glycosuria, independent of insulin. Linagliptin selectively binds DPP-4, prolonging GLP-1 and GIP activity to stimulate glucose-dependent insulin release from beta cells and curb glucagon-mediated gluconeogenesis. Metformin activates AMPK in hepatocytes, inhibiting gluconeogenesis while enhancing peripheral glucose uptake.\n\n\nSynergy amplifies effects—SGLT2 inhibition provides insulin-independent control, DPP-4 boosts prandial responses, and metformin tackles fasting hyperglycemia—resulting in complementary HbA1c drops without overlapping toxicities. Clinical data show this combination yields superior efficacy over dual therapies, with added osmotic diuresis aiding fluid balance.\n\n\nUses and Indications\nLINALIGIP EMPAMET treats type 2 diabetes in adults, as adjunct to diet and exercise, especially when metformin alone or dual therapy inadequately controls glycemia. Primary uses include newly diagnosed patients needing intensification, those with obesity (due to weight loss from glycosuria), and high-risk cardiovascular profiles benefiting from empagliflozin's heart protection. It excels in managing postprandial hyperglycemia, fasting glucose, and preventing complications like nephropathy.\n\n\nPrescribed for patients intolerant to other agents or requiring simplified regimens, it suits Indian demographics with high metabolic syndrome rates. Not for type 1 diabetes or ketoacidosis; renal function (eGFR >45 mL/min) guides initiation.\n\n\nKey Benefits\nLINALIGIP EMPAMET offers multifaceted advantages for long-term diabetes management:\n\nSuperior Glycemic Control: Achieves 1.8% HbA1c reduction in trials, outperforming monotherapies by targeting multiple defects.\n\n\nWeight Loss: Empagliflozin induces 3-5kg loss via caloric excretion, countering metformin's neutral effect.\n\n\nCardiovascular and Renal Protection: Reduces major adverse cardiac events (MACE) by 14% and slows CKD progression, per EMPA-REG outcomes.\n\n\nLow Hypoglycemia Risk: Glucose-dependent actions of linagliptin and empagliflozin minimize lows, unlike sulfonylureas.\n\n\nConvenience: Single-tablet ER dosing improves compliance, vital for busy lifestyles in Jaipur and beyond.\n\n\nBlood Pressure Reduction: Mild diuretic effect lowers systolic BP by 3-5 mmHg.\n\n\nThese benefits enhance quality of life, reducing fatigue, neuropathy risks, and healthcare costs.\n\nSide Effects\nCommon side effects mirror individual components but occur less due to synergy:\n\nGastrointestinal: Metformin ER causes less nausea/diarrhea (10-15%) than IR forms; titrate slowly.\n\n\nGenitourinary: Empagliflozin raises UTI/genital mycotic infection risk (5-10%), managed with hygiene.\n\n\nVolume Depletion: Orthostatic hypotension in 2-3%, especially with diuretics.\n\n\nSerious effects include lactic acidosis (rare, <1/100,000 with metformin in eGFR >30), ketoacidosis (euglycemic, 0.1%), and acute kidney injury. Monitor for dehydration, pancreatitis signs, or bullous pemphigoid with linagliptin. Hypersensitivity rash or bone fractures warrant discontinuation.\n\n\nSide Effect Category\tFrequency\tManagement\nNausea and Diarrhea\tCommon (10%)\tTake with food, slow titration \n\nUTI/Mycotic Infections\tCommon (7%)\tHydration, antifungals \n\nHypoglycemia\tRare (<2%)\tWith insulin, dose adjust \n\nLactic Acidosis\tVery Rare.\tAvoid in renal/hepatic failure \n\nKetoacidosis\tRare (0.1%)\tCheck ketones if nausea \n\nDosage and Administration\nStart with Empagliflozin 10mg/Linagliptin 5mg/Metformin ER 1000mg once daily with morning meal to optimize absorption and reduce GI effects. Titrate metformin to 2000mg max based on tolerance; empagliflozin to 25mg if needed. Swallow whole; no crushing. Adjust for renal impairment (eGFR 30-45: max metformin 1000mg; <30 contraindicated). Elderly start low due to volume sensitivity.\n\n\nMissed dose: Take soon if less than 12 hours late; skip otherwise. Discontinue pre-surgery or contrast use.\n\nPrecautions and Warnings\nAssess eGFR before and 3-6 months after initiation; hold if <45. Caution in dehydration, heart failure, or liver disease risks lactic acidosis. Educate on ketoacidosis symptoms (nausea, fatigue) despite normal glucose. Avoid excessive alcohol; monitor BP in hypertensives. Pregnancy category D—use insulin instead. Breastfeeding is contraindicated.\n\n\nDrug interactions: Adding sulfonylureas/insulin heightens hypoglycemia; rifampin reduces linagliptin levels; ritonavir boosts empagliflozin exposure.\n\nFrequently Asked Questions\nWhat is LINALIGIP EMPAMET used for?\nControls type 2 diabetes via triple action on glucose excretion, incretins, and insulin sensitivity.\n\nDoes it cause weight gain?\nNo—it promotes 2-4 kg loss, unlike some antidiabetics.\n\n\nSafe for kidneys?\nRenal-protective; monitor eGFR.\n\n\nHypoglycemia risk?\nMinimal without sulfonylureas.\n\nConclusion\nLINALIGIP EMPAMET revolutionizes type 2 diabetes care with its potent, convenient triple therapy, delivering glycemic mastery, weight benefits, and cardioprotection unmatched by singles or duos. Backed by landmark trials, it empowers patients toward complication-free lives when integrated with lifestyle changes. Consult physicians for personalized dosing to harness its full potential safely.",
"price": 220.0,
"discountamount": 66.0,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 1,
"_keywords": null,
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 2257,
"imageuri": "https://productimages.withfloats.com/actual/694e60c1db6d50f75e42e875.png",
"tileimageuri": "https://productimages.withfloats.com/tile/694e60c1db6d50f75e42e875.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2025-12-26T09:34:56.604Z",
"updatedon": "2026-03-13T10:59:31Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM//empagliflozin-linagliptin-and-metformin/2257",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "LINALIGIP EMPAMET",
"category": "DIABETIC RANGE",
"tags": [
"empagliflozin 10 mg",
"empagliflozin 25 mg",
"empagliflozin 10 mg uses in hindi",
"empagliflozin 10 mg tablet.",
"type 2 diabetes mellitus.",
"linagliptin",
"Linagliptin 5 mg",
"linagliptin 5 mg uses",
"linagliptin tablet uses",
"Linagliptin 5 mg price",
"Empagliflozin, an SGLT2 inhibitor.",
"Metformin ER reduces hepatic glucose production and improves insulin.",
"LINALIGIP EMPAMET revolutionizes type 2 diabetes.",
"empagliflozin linagliptin and metformin tablets",
"empagliflozin linagliptin metformin combination tablet",
"empagliflozin linagliptin metformin tablets uses",
"empagliflozin linagliptin metformin triple combination",
"empagliflozin linagliptin metformin dosage strength",
"empagliflozin linagliptin metformin sustained release tablet",
"empagliflozin linagliptin metformin medicine for diabetes",
"empagliflozin linagliptin metformin tablet uses",
"empagliflozin linagliptin metformin benefits",
"empagliflozin linagliptin metformin for type 2 diabetes",
"empagliflozin linagliptin metformin blood sugar control",
"empagliflozin linagliptin metformin weight loss benefit",
"what is empagliflozin linagliptin metformin tablet",
"how does empagliflozin linagliptin metformin work",
"empagliflozin linagliptin metformin tablet price in india",
"empagliflozin linagliptin metformin tablet dosage",
"empagliflozin linagliptin metformin before or after food"
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": null,
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.0,
"isnotforsale": false
},
{
"_id": "68822dd35b399ba6097ed11b",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "glimepiride and metformin hydrochloride tablets",
"description": "SEIZMET G0.5 FORTE is a powerful oral antidiabetic medication formulated with a combination of glimepiride and metformin hydrochloride. This dual-action therapy is specifically designed for patients with type 2 diabetes mellitus who are unable to control their blood sugar levels with diet and exercise alone. The combination works in synergy to manage blood glucose effectively, reduce insulin resistance, and improve overall glycemic control.\n\nGlimepiride and metformin hydrochloride tablets are a combination medication used to treat type 2 diabetes. They work by helping the pancreas release more insulin and by reducing the amount of sugar produced by the liver, while also making the body more sensitive to insulin.\n\nWhat is SEIZMET G0.5 FORTE?\nSEIZMET G0.5 FORTE contains two active ingredients:\n\nGlimepiride (0.5 mg): A sulfonylurea class drug that stimulates the beta cells of the pancreas to release insulin.\n\nMetformin Hydrochloride: A biguanide that works primarily by suppressing hepatic glucose production and increasing insulin sensitivity in muscles.\n\nTogether, this combination addresses both insulin deficiency and resistance—two key factors in type 2 diabetes.\n\nUses of SEIZMET G0.5 FORTE:\n\nEffective in managing type 2 diabetes mellitus\n\nHelps in reducing fasting and postprandial blood glucose levels\n\nUsed as monotherapy or in combination with other antidiabetic agents\n\nReduces the risk of diabetic complications such as nephropathy, retinopathy, and cardiovascular disease\n\nSide Effects of SEIZMET G0.5 FORTE:\nLike all medications, glimepiride and metformin hydrochloride tablets may cause side effects in some patients. Common side effects include:\n\nNausea or vomiting\n\nDiarrhea\n\nHypoglycemia (low blood sugar)\n\nHeadache\n\nDizziness\n\nMetallic taste in the mouth\n\nAbdominal discomfort\n\nIn rare cases, it may cause lactic acidosis, a serious condition related to metformin accumulation.\n\nPrecautions Before Using SEIZMET G0.5 FORTE:\n\nAlways take the medication exactly as prescribed by your doctor.\n\nInform your physician if you have a history of liver or kidney disorders, heart disease, or alcohol abuse.\n\nAvoid excessive alcohol consumption while on this medication as it increases the risk of lactic acidosis.\n\nNot recommended for patients with type 1 diabetes or diabetic ketoacidosis.\n\nRegularly monitor your blood sugar and kidney function.\n\nThis medicine should be used during pregnancy only if absolutely necessary and under medical supervision.\n\nDrug Interactions: What Drugs Interact with SEIZMET G0.5 FORTE?\nCertain medications can interact with glimepiride and metformin, affecting their efficacy or increasing the risk of side effects. These include:\n\nBeta-blockers (e.g., propranolol) – may mask hypoglycemia symptoms\n\nDiuretics – may impair blood sugar control\n\nACE inhibitors – may increase the blood glucose-lowering effect\n\nCorticosteroids – may reduce the effectiveness of the medication\n\nAntipsychotics (e.g., olanzapine)\n\nAlcohol – increases the risk of lactic acidosis\n\nCimetidine – may raise metformin levels in the body\n\nAlways inform your healthcare provider about all medications, supplements, or herbal products you are taking.\n\nConclusion:\nSEIZMET G0.5 FORTE is a trusted, effective choice for managing type 2 diabetes, offering the combined benefits of glimepiride and metformin hydrochloride tablets. With dual mechanisms—enhancing insulin secretion and improving insulin sensitivity—it delivers comprehensive glycemic control. When taken as directed and with regular monitoring, SEIZMET G0.5 FORTE can be a valuable part of a diabetic patient’s treatment regimen, contributing to a healthier, more balanced life.\n\nFor best results, pair this medication with a proper diet, regular physical activity, and periodic blood glucose testing. Always consult your healthcare provider for personalized advice.",
"price": 125.0,
"discountamount": 38.0,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 1,
"_keywords": null,
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 2151,
"imageuri": "https://productimages.withfloats.com/actual/68822dd8296c4d19d55e8535.png",
"tileimageuri": "https://productimages.withfloats.com/tile/68822dd8296c4d19d55e8535.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2025-07-24T12:57:55.385Z",
"updatedon": "2026-05-23T06:33:46.886Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM//glimepiride-and-metformin-hydrochloride-tablets/2151",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "SEIZMET G 0.5 FORTE",
"category": "DIABETIC RANGE",
"tags": [
"glimepiride and metformin hydrochloride tablets",
"type 2 diabetes mellitus",
"blood glucose",
"glycemic control",
"blood sugar control",
"glimepiride and metformin hydrochloride tablets",
"glimepiride and metformin hydrochloride tablets uses in hindi",
"glimepiride and metformin hydrochloride tablets uses",
"glimepiride and metformin hydrochloride tablets price",
"glimepiride and metformin hydrochloride tablets brand name"
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": null,
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.001,
"isnotforsale": false
},
{
"_id": "665ef5bda743fd235821deeb",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "gliclazide 80 mg metformin 500 mg",
"description": "GLICLAGLAZE M 80 \ngliclazide (80 mg), metformin (500 mg)\nIntroduction\nGLICLAGLAZE M 80 is a specialized medication formulated for individuals diagnosed with Type 2 diabetes, aiming to enhance blood sugar regulation. This oral medication combines Gliclazide (80 mg) with Metformin (500 mg), two effective antidiabetic agents that provide a synergistic effect to control high blood sugar.\n\nMechanism of Action\n\nGliclazide (80 mg): Belonging to the sulfonylurea class, gliclazide works by increasing insulin secretion from the pancreatic beta cells. It promotes a decrease in blood glucose levels and enhances the action of insulin in the body. Additionally, Gliclazide improves blood flow and has protective effects against the vascular complications of diabetes.\nMetformin (500 mg): Metformin reduces hepatic glucose production and improves insulin sensitivity by enhancing peripheral glucose uptake, particularly in muscle cells. This action helps lower blood glucose levels without the risk of inducing hypoglycemia and is associated with a potential reduction in body weight.\nBenefits\nGLICLAGLAZE M 80 offers a robust approach to managing Type 2 diabetes by targeting different aspects of the disease. The combination of Gliclazide and Metformin in this medication helps to control blood sugar more effectively than either component alone, potentially lowering the patient's risk of diabetes-related complications.\n\nDosage and Administration\n\nDosage: The starting dose should be adjusted based on the patient’s previous medication regimen, effectiveness, and tolerability. Dose adjustments should be made based on glycemic control, as assessed by regular monitoring of blood glucose levels.\nAdministration: It is recommended to take GLICLAGLAZE M 80 with meals to maximize drug absorption and minimize potential gastrointestinal side effects.\nSide Effects\nPotential side effects of GLICLAGLAZE M 80 include gastrointestinal symptoms like nausea and diarrhea, which usually improve over time. The risk of hypoglycemia exists but is moderated by the inclusion of metformin.\n\nConclusion\nGLICLAGLAZE M 80 represents an effective treatment solution for managing Type 2 diabetes, combining two powerful antidiabetic agents to improve glycemic control and reduce the risk of diabetes complications. Patients should maintain regular consultations with their healthcare provider to tailor their treatment plan according to their specific needs, ensuring the best possible outcomes in diabetes management.\nFor further information:\nEMAIL: info@sterispharma.com / contact@sterispharma.com \n Order Now\n\n\n\n\n\n\n",
"price": 137.0,
"discountamount": 41.0,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 7,
"_keywords": [
"risk",
"time",
"Order",
"meals",
"EMAIL",
"nausea",
"500 mg",
"Action",
"patient",
"disease",
"diarrhea",
"Benefits",
"decrease",
"Mechanism",
"Metformin",
"component",
"inclusion",
"Conclusion",
"blood flow",
"gliclazide",
"individuals",
"information",
"body weight",
"combination",
"Introduction",
"muscle cells",
"tolerability",
"sterispharma",
"hypoglycemia",
"sterisonline",
"starting dose",
"effectiveness",
"CALL/WHATSAPP",
"GLICLAGLAZE M",
"treatment plan",
"specific needs",
"Type 2 diabetes",
"oral medication",
"robust approach",
"drug absorption",
"high blood sugar",
"Dose adjustments",
"glycemic control",
"different aspects",
"insulin secretion",
"regular monitoring",
"sulfonylurea class",
"synergistic effect",
"protective effects",
"healthcare provider",
"insulin sensitivity",
"potential reduction",
"diabetes management",
"blood glucose levels",
"regular consultations",
"pancreatic beta cells",
"Administration Dosage",
"best possible outcomes",
"blood sugar regulation",
"Potential side effects",
"specialized medication",
"diabetes complications",
"vascular complications",
"gastrointestinal symptoms",
"peripheral glucose uptake",
"hepatic glucose production",
"previous medication regimen",
"effective treatment solution",
"diabetes-related complications",
"two powerful antidiabetic agents",
"two effective antidiabetic agents",
"potential gastrointestinal side effects"
],
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 1287,
"imageuri": "https://productimages.withfloats.com/actual/665ef5c0ca75628a5853ff45.png",
"tileimageuri": "https://productimages.withfloats.com/tile/665ef5c0ca75628a5853ff45.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2024-06-04T11:08:45.584Z",
"updatedon": "2026-03-13T05:37:48.45Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM//gliclazide-80-mg-metformin-500-mg/1287",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "GLICLAGLAZE M 80 ",
"category": "DIABETIC RANGE",
"tags": [
"gliclazide 80 mg metformin 500 mg tablet uses",
"gliclazide 80 mg metformin 500 mg dosage for diabetes",
"gliclazide metformin 80 mg 500 mg side effects",
"gliclazide metformin 80 mg 500 mg how it works"
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": "",
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.001,
"isnotforsale": false
},
{
"_id": "6ad74702e53c888beeab308d",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "Empagliozin 10 mg, Sitagliptin 100 mg and Metformin hydrochloride 1000 mg ER Tablets",
"description": "GLIEMPAFLOZIN 3D 10 is a triple-combination antidiabetic tablet containing Empagliflozin 10 mg, Sitagliptin 100 mg, and Metformin Hydrochloride Extended Release (ER) 1000 mg. This combination is intended for the management of type 2 diabetes mellitus in appropriately selected patients under the supervision of a qualified healthcare professional.\n\nThe three active ingredients work through different mechanisms to help regulate blood glucose levels. Empagliflozin helps the kidneys eliminate glucose through urine, Sitagliptin supports glucose-dependent insulin regulation, and Metformin helps reduce glucose production in the liver while improving insulin sensitivity.\n\nBy combining these ingredients in one tablet, GLIEMPAFLOZIN 3D 10 provides a multi-mechanism approach to blood glucose management. Its suitability depends on the patient's clinical condition, kidney function, existing treatment, and the approved prescribing information.\n\nComposition of GLIEMPAFLOZIN 3D 10\nEach tablet contains the following stated active ingredients:\n\nEmpagliflozin 10 mg: A sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces glucose reabsorption by the kidneys and increases glucose excretion through urine.\nSitagliptin 100 mg: A dipeptidyl peptidase-4 (DPP-4) inhibitor that helps regulate insulin and glucagon responses according to blood glucose levels.\nMetformin Hydrochloride ER 1000 mg: An extended-release biguanide that primarily reduces glucose production in the liver and improves the body's response to insulin.\nThe exact formulation, excipients, approved indications, and administration instructions should be confirmed from the product packaging and official prescribing information.\n\nKey Features of GLIEMPAFLOZIN 3D 10 Tablets\nGLIEMPAFLOZIN 3D 10 combines three established antidiabetic medicines with complementary mechanisms of action.\n\nTriple-combination formulation: Contains Empagliflozin, Sitagliptin, and Metformin Hydrochloride ER.\nMultiple glucose-control pathways: Targets different processes involved in blood glucose regulation.\nExtended-release metformin: Provides a formulation designed to release Metformin gradually over time.\nOral tablet dosage form: Allows administration according to the prescribed regimen.\nIndividualized diabetes management: May be considered when a healthcare professional determines that all three ingredients are appropriate.\nThe combination is not suitable for every person with diabetes. Treatment decisions should be based on individual medical needs and the approved product information.\n\nUses of GLIEMPAFLOZIN 3D 10\nGLIEMPAFLOZIN 3D 10 is intended for the management of type 2 diabetes mellitus, subject to its approved indications and the prescribing healthcare professional's assessment.\n\nType 2 diabetes is a chronic metabolic condition characterized by impaired insulin action and, in many patients, insufficient insulin production. Persistently elevated blood glucose can increase the risk of complications affecting the eyes, kidneys, nerves, heart, and blood vessels.\n\nThe three active ingredients in GLIEMPAFLOZIN 3D 10 address different aspects of glucose regulation. A healthcare professional may consider this combination when multiple medicines are required to achieve an individual's treatment goals and when the combination is clinically appropriate.\n\nThe medicine should be used as part of a comprehensive diabetes-management plan that may include balanced nutrition, regular physical activity, blood glucose monitoring, and routine medical assessments. It is not intended for the treatment of type 1 diabetes or diabetic ketoacidosis.\n\nHow Does GLIEMPAFLOZIN 3D 10 Work?\n1. Empagliflozin 10 mg\nEmpagliflozin belongs to the SGLT2 inhibitor class. It blocks a protein responsible for reabsorbing glucose filtered by the kidneys. This allows more glucose to be eliminated through urine, helping reduce blood glucose levels.\n\nEmpagliflozin has also demonstrated cardiovascular and kidney benefits in certain eligible patient populations. Whether these benefits apply to an individual depends on their clinical condition and the applicable prescribing information.\n\n2. Sitagliptin 100 mg\nSitagliptin inhibits the DPP-4 enzyme, which breaks down incretin hormones. By increasing incretin activity, Sitagliptin supports insulin release when blood glucose is elevated and helps regulate glucagon secretion. These actions contribute to blood glucose control.\n\n3. Metformin Hydrochloride ER 1000 mg\nMetformin primarily reduces glucose production in the liver and improves insulin sensitivity. The extended-release formulation is designed to release the medicine gradually over time.\n\nTogether, these ingredients target several pathways involved in type 2 diabetes. Their combined effectiveness and safety depend on appropriate prescribing, correct administration, and regular monitoring.\n\nPotential Benefits of GLIEMPAFLOZIN 3D 10\nWhen prescribed for an appropriate patient, GLIEMPAFLOZIN 3D 10 may offer the following treatment advantages:\n\nMultiple mechanisms of action: Combines three medicines that influence different aspects of glucose regulation.\nBlood glucose management: Helps improve glycemic control in eligible adults with type 2 diabetes.\nCombination therapy: May simplify a treatment regimen compared with taking the same ingredients as separate tablets.\nExtended-release component: Includes Metformin Hydrochloride ER for gradual drug release.\nPersonalized treatment options: May be considered when a healthcare professional determines that triple therapy is appropriate.\nIndividual outcomes vary, and the medicine does not replace a suitable diet, physical activity, or routine diabetes care.\n\nDirections for Use\nTake GLIEMPAFLOZIN 3D 10 only as prescribed by your healthcare professional.\n\nFollow the prescribed dose and administration schedule.\nTake the tablet with food if directed by the product labeling or your prescriber.\nSwallow the extended-release tablet whole unless the specific product instructions state otherwise. Do not crush, chew, or split it without professional guidance.\nDo not change the dose or stop treatment without consulting your prescriber.\nAttend recommended appointments for kidney-function assessment and blood glucose monitoring.\nIf you miss a dose, follow the official patient information or ask your healthcare professional or pharmacist what to do. Do not take an extra dose to compensate for a missed dose unless specifically instructed.\n\nPrecautions and Safety Information\nGLIEMPAFLOZIN 3D 10 is a prescription medicine and may not be suitable for everyone.\n\nKidney function: Kidney function should be assessed before and during treatment as appropriate. Metformin and Empagliflozin have important kidney-related prescribing considerations.\n\nDehydration: Empagliflozin increases glucose excretion through urine and may increase urination. Patients at risk of dehydration or low blood pressure should discuss appropriate precautions with their healthcare professional.\n\nGenital and urinary infections: Empagliflozin may increase the risk of genital fungal infections and can be associated with urinary tract infections.\n\nLactic acidosis: Metformin can rarely cause a serious condition called lactic acidosis. Risk may increase with significant kidney impairment, severe dehydration, certain acute illnesses, or excessive alcohol intake.\n\nPancreatitis: Pancreatitis has been reported in patients taking Sitagliptin. Severe, persistent abdominal pain requires prompt medical assessment.\n\nHypoglycemia: Low blood glucose may occur, particularly when the combination is used with insulin or insulin secretagogues such as sulfonylureas.\n\nInform your healthcare professional about existing medical conditions, all medicines you take, pregnancy or breastfeeding, planned surgery, prolonged fasting, and upcoming procedures involving iodinated contrast. Follow professional instructions about temporary medicine interruption during acute illness or other high-risk situations.\n\nSeek urgent medical care for severe abdominal pain, difficulty breathing, persistent vomiting, severe dehydration, or other serious symptoms.\n\nWhy Choose GLIEMPAFLOZIN 3D 10?\nGLIEMPAFLOZIN 3D 10 brings together Empagliflozin 10 mg, Sitagliptin 100 mg, and Metformin Hydrochloride ER 1000 mg in a triple-combination tablet intended for selected patients with type 2 diabetes.\n\nFor pharmaceutical websites, pharmacies, distributors, and healthcare professionals, clear information about composition, mechanism of action, potential uses, and precautions supports responsible product awareness.\n\nAlways refer to the approved product label for the exact composition, indications, dosage, contraindications, storage requirements, and instructions for use.\n\nConclusion\nGLIEMPAFLOZIN 3D 10 Tablets combine Empagliflozin 10 mg, Sitagliptin 100 mg, and Metformin Hydrochloride ER 1000 mg to target multiple pathways involved in blood glucose regulation. The combination may be appropriate for selected adults with type 2 diabetes under medical supervision.\n\nFor complete information about dosage, contraindications, warnings, storage, and approved indications, consult the official product packaging and prescribing information. Use this medicine only under the direction of a qualified healthcare professional.\n\nFrequently Asked Questions (FAQs)\n1. What is GLIEMPAFLOZIN 3D 10?\n\nGLIEMPAFLOZIN 3D 10 is a combination tablet containing Empagliflozin 10 mg, Sitagliptin 100 mg, and Metformin Hydrochloride ER 1000 mg.\n\n2. What is GLIEMPAFLOZIN 3D 10 used for?\n\nIt is intended for the management of type 2 diabetes mellitus in patients for whom this combination is considered appropriate by a healthcare professional.\n\n3. How does GLIEMPAFLOZIN 3D 10 work?\n\nEmpagliflozin increases urinary glucose excretion, Sitagliptin supports glucose-dependent insulin regulation, and Metformin reduces glucose production in the liver and improves insulin sensitivity.\n\n4. Can GLIEMPAFLOZIN 3D 10 replace diet and exercise?\n\nNo. Medication should be combined with an individualized diet, physical activity, and monitoring plan recommended by a healthcare professional.\n\n5. Is GLIEMPAFLOZIN 3D 10 suitable for everyone with diabetes?\n\nNo. Suitability depends on the type of diabetes, kidney function, other medical conditions, concurrent medicines, and approved prescribing information.\n\n",
"price": 210.0,
"discountamount": 147.0,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 1,
"_keywords": null,
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 2505,
"imageuri": "https://productimages.withfloats.com/actual/6ad7470422551901df6e5493.png",
"tileimageuri": "https://productimages.withfloats.com/tile/6ad7470422551901df6e5493.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2026-10-20T10:48:34.116Z",
"updatedon": "2026-10-20T10:48:34.116Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM//empagliozin-10-mg-sitagliptin-100-mg-and-metformin-hydrochloride-1000-mg-er-tablets/2505",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "GLIEMPAFLOZIN 3D 10",
"category": "DIABETIC RANGE",
"tags": [],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": null,
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.0,
"isnotforsale": false
},
{
"_id": "6ad7442bf24c5a4bbccf4b10",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "Empagliflozin,Sitagliptin And Metformin Hydrochloride (ER) Tablets",
"description": "GLIEMPAFLOZIN 3D 25 is a combination pharmaceutical product containing Empagliflozin 25 mg, Sitagliptin 100 mg, and Metformin Hydrochloride Extended Release (ER) 1000 mg. This triple-combination formulation is intended for the management of type 2 diabetes mellitus in appropriate patients, as determined by a qualified healthcare professional.\n\nThe three active ingredients work through different mechanisms to help control blood glucose levels. Empagliflozin belongs to the sodium-glucose cotransporter 2 (SGLT2) inhibitor class, Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, and Metformin is a biguanide antidiabetic medicine. Together, these ingredients target different pathways involved in glucose regulation.\n\nGLIEMPAFLOZIN 3D 25 provides a combination of three established antidiabetic agents in a single tablet. Its suitability depends on the patient's blood glucose levels, kidney function, current diabetes treatment, medical history, and the approved prescribing information.\n\nComposition of GLIEMPAFLOZIN 3D 25\nEach tablet contains the following stated active ingredients:\n\nEmpagliflozin 25 mg: An SGLT2 inhibitor that helps the kidneys remove glucose from the bloodstream through urine.\nSitagliptin 100 mg: A DPP-4 inhibitor that increases the activity of incretin hormones involved in glucose-dependent insulin release and glucagon regulation.\nMetformin Hydrochloride ER 1000 mg: An extended-release biguanide that primarily reduces glucose production in the liver and improves the body's response to insulin.\nThe exact formulation, excipients, administration instructions, and approved indications should be verified against the product packaging and official prescribing information.\n\nKey Features of GLIEMPAFLOZIN 3D 25\nGLIEMPAFLOZIN 3D 25 combines three antidiabetic ingredients with complementary mechanisms of action.\n\nTriple-combination formulation: Contains Empagliflozin, Sitagliptin, and Metformin Hydrochloride ER.\nMultiple glucose-control pathways: The ingredients act through different mechanisms involved in blood glucose regulation.\nExtended-release metformin: The ER formulation is designed to release metformin over an extended period.\nOral tablet dosage form: Provides oral administration according to the prescribed regimen.\nIndividualized diabetes management: May be considered by a healthcare professional when combination therapy is appropriate.\nThe benefits of this combination depend on the patient's clinical needs and the suitability of all three ingredients.\n\nUses of GLIEMPAFLOZIN 3D 25 Tablets\nGLIEMPAFLOZIN 3D 25 is intended for the management of type 2 diabetes mellitus, subject to the product's approved indications and the prescribing healthcare professional's judgment.\n\nType 2 diabetes is a chronic metabolic condition in which the body does not use insulin effectively or does not produce enough insulin to maintain healthy blood glucose levels. Long-term elevated blood glucose can increase the risk of complications affecting the eyes, kidneys, nerves, heart, and blood vessels.\n\nThe three medicines in GLIEMPAFLOZIN 3D 25 target different aspects of glucose regulation. A healthcare professional may consider a combination regimen when an individual's treatment goals are not adequately achieved with a simpler regimen or when the combination is otherwise clinically appropriate.\n\nThe medicine should be used alongside an individualized diabetes-management plan that may include a balanced diet, physical activity, glucose monitoring, and regular medical follow-up. It is not intended for the treatment of type 1 diabetes or diabetic ketoacidosis.\n\nHow Does GLIEMPAFLOZIN 3D 25 Work?\nThe three active ingredients contribute to blood glucose management through distinct mechanisms.\n\n1. Empagliflozin 25 mg\nEmpagliflozin inhibits SGLT2, a protein responsible for reabsorbing much of the glucose filtered by the kidneys. By reducing glucose reabsorption, it increases glucose excretion through urine and helps lower blood glucose levels.\n\nEmpagliflozin has also demonstrated cardiovascular and kidney benefits in certain eligible patient populations. These benefits depend on the patient's condition and the applicable prescribing information and should not be assumed to apply identically to every patient.\n\n2. Sitagliptin 100 mg\nSitagliptin inhibits the DPP-4 enzyme, which breaks down incretin hormones. Increasing incretin activity helps stimulate insulin release when blood glucose is elevated and reduces glucagon secretion when appropriate. This helps regulate glucose levels, particularly after meals.\n\n3. Metformin Hydrochloride ER 1000 mg\nMetformin primarily decreases glucose production in the liver and improves insulin sensitivity. The extended-release formulation is designed to release the medicine gradually over time.\n\nBy combining these mechanisms, GLIEMPAFLOZIN 3D 25 targets several pathways involved in type 2 diabetes. Its overall effectiveness and safety depend on appropriate patient selection, dosing, and ongoing monitoring.\n\nPotential Benefits of GLIEMPAFLOZIN 3D 25\nWhen prescribed for an appropriate patient, this combination may offer the following treatment advantages:\n\nMultiple mechanisms of action: Addresses glucose regulation through three different pharmacological pathways.\nBlood glucose management: Helps improve glycemic control in eligible adults with type 2 diabetes.\nOral combination therapy: Combines three medicines in one tablet, which may simplify a prescribed regimen compared with taking each ingredient separately.\nExtended-release component: Includes Metformin Hydrochloride ER for gradual drug release.\nIndividualized treatment options: May be considered when a healthcare professional determines that all three ingredients are appropriate.\nThese potential advantages do not guarantee a particular result. Treatment effectiveness depends on adherence, diet, physical activity, individual health status, and medical supervision.\n\nDirections for Use\nGLIEMPAFLOZIN 3D 25 should be taken only as prescribed by a qualified healthcare professional.\n\nFollow the prescribed dose and administration schedule.\nTake the tablet with food if directed by the product labeling or prescriber.\nSwallow the extended-release tablet whole unless the specific product instructions state otherwise. Do not crush, chew, or split it without professional guidance.\nDo not change the dose or discontinue treatment without consulting your prescriber.\nAttend recommended appointments for blood glucose monitoring and kidney-function assessment.\nIf a dose is missed, follow the official patient information or ask your healthcare professional or pharmacist for advice. Do not take an extra dose to compensate for a missed dose unless specifically instructed.\n\nPrecautions and Safety Information\nGLIEMPAFLOZIN 3D 25 is a prescription medicine and is not suitable for everyone.\n\nKidney function: Kidney function should be assessed before and during treatment as appropriate. Metformin and Empagliflozin have important renal considerations, and the combination may be unsuitable at certain levels of kidney impairment.\n\nDehydration: Empagliflozin increases glucose excretion through urine and may increase urination. Patients should discuss dehydration risk, low blood pressure, and fluid intake with their healthcare professional.\n\nGenital and urinary infections: Empagliflozin can increase the risk of genital fungal infections and may be associated with urinary tract infections.\n\nLactic acidosis: Metformin can rarely cause a serious condition called lactic acidosis. Risk may increase with significant kidney impairment, severe dehydration, certain acute illnesses, excessive alcohol intake, or other predisposing conditions.\n\nPancreatitis: Pancreatitis has been reported in patients taking Sitagliptin. Severe, persistent abdominal pain requires prompt medical assessment.\n\nLow blood glucose: The risk of hypoglycemia may increase when this combination is used with insulin or insulin secretagogues, such as sulfonylureas.\n\nInform your healthcare professional about existing medical conditions, all medicines you take, pregnancy or breastfeeding, planned surgery, prolonged fasting, or an upcoming medical procedure involving iodinated contrast. Follow professional instructions about temporary medicine interruption during acute illness or other high-risk situations.\n\nSeek urgent medical care for severe abdominal pain, difficulty breathing, unusual weakness, persistent vomiting, severe dehydration, or other serious symptoms.\n\nWhy Choose GLIEMPAFLOZIN 3D 25?\nGLIEMPAFLOZIN 3D 25 brings together Empagliflozin, Sitagliptin, and Metformin Hydrochloride ER in a triple-combination tablet designed for the management of type 2 diabetes in appropriately selected patients.\n\nFor pharmaceutical product catalogues, distributors, pharmacies, and healthcare professionals, accurate information about the composition, mechanism of action, approved indications, and safety profile supports responsible product awareness.\n\nTreatment decisions should always be based on the patient's medical assessment and the approved product information.\n\nConclusion\nGLIEMPAFLOZIN 3D 25 Tablets combine Empagliflozin 25 mg, Sitagliptin 100 mg, and Metformin Hydrochloride ER 1000 mg to target multiple pathways involved in blood glucose regulation. This combination may be appropriate for selected adults with type 2 diabetes under medical supervision.\n\nFor complete information about dosage, contraindications, warnings, storage, and approved indications, consult the official product packaging and prescribing information. Use this medicine only under the direction of a qualified healthcare professional.\n\nFrequently Asked Questions (FAQs)\n1. What is GLIEMPAFLOZIN 3D 25?\n\nGLIEMPAFLOZIN 3D 25 is a combination tablet containing Empagliflozin 25 mg, Sitagliptin 100 mg, and Metformin Hydrochloride ER 1000 mg.\n\n2. What is GLIEMPAFLOZIN 3D 25 used for?\n\nIt is intended for the management of type 2 diabetes mellitus in patients for whom the combination is considered appropriate by a healthcare professional.\n\n3. How does GLIEMPAFLOZIN 3D 25 work?\n\nEmpagliflozin increases urinary glucose excretion, Sitagliptin supports glucose-dependent insulin regulation, and Metformin reduces glucose production in the liver and improves insulin sensitivity.\n\n4. Can GLIEMPAFLOZIN 3D 25 replace diet and exercise?\n\nNo. Medication should be combined with an individualized diet, physical activity, and monitoring plan as recommended by a healthcare professional.\n\n5. Is GLIEMPAFLOZIN 3D 25 suitable for everyone with diabetes?\n\nNo. Its suitability depends on the type of diabetes, kidney function, other medical conditions, concurrent medicines, and the approved prescribing information.",
"price": 230.0,
"discountamount": 69.0,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 1,
"_keywords": null,
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 2504,
"imageuri": "https://productimages.withfloats.com/actual/6ad7442d6e565c5fe6e5b7cb.png",
"tileimageuri": "https://productimages.withfloats.com/tile/6ad7442d6e565c5fe6e5b7cb.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2026-10-20T10:36:27.325Z",
"updatedon": "2026-10-20T10:36:27.325Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM//empagliflozin-sitagliptin-and-metformin-hydrochloride-er-tablets/2504",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "GLIEMPAFLOZIN 3D 25",
"category": "DIABETIC RANGE",
"tags": [],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": null,
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.0,
"isnotforsale": false
}
],
"hasmoreitems": false,
"isapirequest": false,
"totalresults": 27,
"query": null,
"floatingpoint": null
}